Why Hims & Hers Stock Dropped Today
Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Hims & Hers price target raised to $21 from $18 at BofA
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Hims & Hers Buys Lab to Expand Into At-Home Blood Testing
Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Hims & Hers Health Shares Hit All-Time High After Testing Facility Buy
Hims & Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ.
Her Campus1d
Hims & Hers Super Bowl Ad Hypocritically Fuels Fatphobia
The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...
Hims & Hers: The Pros And Cons Of The Trybe Acquisition
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...